68Ga-RM26-RGD PET/CT Imaging in the GRPR and αvβ3 Positive Tumor Patients

Summary

Based on the high expression of specific receptors on the surface of diseased tissues and neovascularization, noninvasive targeted molecular imaging can be used to visualize lesions in vitro by combining specific ligands labeled with short half-life isotopes. In this study, a novel dual-target imaging agent 68Ga-RM26-RGD was used for clinical study of tumor PET/CT imaging to further verify its clinical application value.

Eligibility

Inclusion Criteria:

* patients with confirmed or suspected breast/brain/prostate cancer;
* 68Ga-RM26-RGD and 18F-FDG(or 68Ga-RM26 or 68Ga-RGD) PET/CT within 2 week;
* signed written consent.

Exclusion Criteria:

* pregnancy;
* breastfeeding;
* any medical condition that in the opinion of the investigator may significantly interfere with study compliance.

Conditions5

Interventions4

Related trials

• 68Ga-FAPI-RGD PET/CT Imaging in the Lung Cancer Patients — Peking Union Medical College Hospital
• A Molecular Probe Targeting BCMA for the Clinical Diagnosis of Multiple Myeloma — Peking University First Hospital
• CD147 Targeting Nanobody Probe for PET Imaging in Solid Tumors — Hua Zhu
• CLDN18.2 Targeting Nanobody Probe for PET Imaging in Solid Tumors — Peking University Cancer Hospital & Institute
• Dosimetry and Preliminary Clinical Application Study of a Novel Probe Targeting CD73 — First Affiliated Hospital of Fujian Medical University
• Lung Nodule Detection Using Ultra-long FOV PET/CT — University Medical Center Groningen
• Nectin-4 Specific LMW PET Probe Imaging in Urothelial Carcinoma — Peking University Cancer Hospital & Institute
• PD-L1 Specific [68Ga]Ga-THP-PDL1-3 Probe for PET Imaging in Solid Tumors — Hua Zhu

Browse More Trials